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The abbreviations used are: acetyl-CoA carboxylase (ACC), ATP-binding cassette 
transporters C1 (ABCC1) and G1 (ABCG1), Basic-helice-loop-helice leucine zipper (bHLH-
ZiP), carbohydrate responsive element binding protein (ChREBP), carbohydrate responsive 
element (ChoRE), chick embryo hepatocytes (CEH), constitutive androstane receptor (CAR), 
CREB binding protein (CBP), dominant negative form of Mlx (dn-Mlx), estrogen receptor α 
(ERα), fatty acid synthase (FAS), farnesoid X receptor (FXR), glucokinase (GK), glucose 6-
phosphate (G6P), glucose 6 phosphatase (G6Pase), glucose 6 phosphate dehydrogenase 
G6PDH), glucose-sensing module (GSM), glucose response conserved element (GRACE), 
glycogen storage disease type 1 (GSD-1), hepatocyte nuclear factor 4 (HNF4), ligand binding 
domain (LBD), liver-pyruvate kinase (L-PK), liver X receptor (LXR), liver X receptor 
element (LXRE), low glucose inhibitory domain (LID), Max-like protein X (Mlx), Mondo 
Conserved Region (MCR), nuclear export signal (NES), nuclear localization signal (NLS), 
propylthiouracil (PTU), protein kinase (PKA), peroxisome proliferator-activated receptors 
(PPARs), phosphatase 2A (PP2A), pregnane X receptor (PXR), real time quantitative 
polymerase chain reaction (RTQ-PCR), retinoid X receptor (RXR), thyroid hormones (TH), 
thyroid hormone receptor (TR), sterol regulatory element (SRE), sterol regulatory element 
binding protein-1c (SREBP-1c), stearoyl CoA desaturase 1 (SCD1), streptozotocin (STZ), 
thyroid hormones (TH). triglycerides (TG), vitamin D receptor (VDR).   
 
Key words: ChREBP, nuclear receptors, glucose metabolism, lipogenesis  
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Abstract 
 
There is a worldwide epidemic of obesity and type 2 diabetes, two major public health 
concerns associated with alterations in both insulin and glucose signaling pathways. Glucose 
is not only an energy source but also controls the expression of key genes involved in 
energetic metabolism, through the glucose-signaling transcription factor, Carbohydrate 
Responsive Element Binding Protein (ChREBP). ChREBP has emerged as a central regulator 
of de novo fatty acid synthesis (lipogenesis) in response to glucose under both physiological 
and physiopathological conditions. Glucose activates ChREBP by regulating its entry from 
the cytosol to the nucleus, thereby promoting its binding to carbohydrate responsive element 
(ChoRE) in the promoter regions of glycolytic (L-PK) and lipogenic genes (ACC and FAS). 
We have previously reported that the inhibition of ChREBP in liver of obese ob/ob mice 
improves the metabolic alterations linked to obesity, fatty liver and insulin-resistance. 
Therefore, regulating ChREBP activity could be an attractive target for lipid-lowering 
therapies in obesity and diabetes. However, before this is possible, a better understanding of 
the mechanism(s) regulating its activity is needed. In this review, we summarize recent 
findings on the role and regulation of ChREBP and particularly emphasize on the cross-
regulations that may exist between key nuclear receptors (LXR, TR, HNF4α) and ChREBP 
for the control of hepatic glucose metabolism. These novel molecular cross-talks may open 
the way to new pharmacological opportunities.  
 
 
Research highlights 
 
• ChREBP is a central transcriptional regulator of hepatic de novo fatty acid synthesis  
• ChREBP inhibition in liver of obese ob/ob mice improves hepatic steatosis and  
insulin-resistance 
• ChREBP represents an attractive target for lipid-lowering therapies in obesity and 
diabetes  
• Cross-regulations exist between ChREBP and liver nuclear receptors for the control of 
hepatic glucose and lipid metabolism  
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• Identification of novel molecular cross-talks between ChREBP and nuclear receptors 
may open the way to new pharmacological opportunities  
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Introduction 
In mammals, the liver is responsible for the conversion of excess dietary 
carbohydrates into triglycerides (TG), through de novo lipogenesis. Appropriate control of 
lipogenesis is crucial since excess fatty acid storage leads to hepatic steatosis and other related 
metabolic diseases [1]. Increased lipogenesis results from transcriptional activation of many 
genes encoding glycolytic and lipogenic enzymes including glucokinase (GK) [2], liver-
pyruvate kinase (L-PK) [3], acetyl CoA carboxylase (ACC) [4], fatty acid synthase (FAS) [5] 
and stearoyl CoA desaturase (SCD1) [6]. Uptake of glucose by liver is concomitant with 
increased concentrations of substrates such as glucose but also in the ratio of pancreatic 
hormones: insulin / glucagon. Until recently, it was thought that insulin and glucagon were 
the main transcriptional regulators of glycolytic and lipogenic gene expression (respectively 
up and down regulators). 
The transcriptional effect of insulin is mediated by sterol regulatory element binding 
protein-1c (SREBP-1c) [7], a transcription factor from the basic-helix-loop-helix-leucine 
zipper (bHLH/LZ) transcription factor family. SREBP-1c induces lipogenic genes by its 
capacity to bind a sterol response element (SRE) present in the promoter of its target genes 
[8]. SREBP-1c is regulated by itself but also by liver X receptors (LXRs) [9]. LXRs are 
ligand-activated transcription factors that belong to the nuclear receptor super-family. LXRs, 
which activity is controlled by cholesterol metabolites called oxysterols, are important 
regulators of the lipogenic pathway, since LXRs are central for the transcriptional control of 
SREBP-1c by insulin [10] and lipogenic genes such as FAS and SCD1 [11]. Transgenic mice 
that overexpress SREBP-1c in liver or mice gavaged by an agonist of LXRs have an increased 
expression of most lipogenic genes and develop liver steatosis [12]. Interestingly, mice devoid 
of SREBP-1c result only in a 50% reduction in fatty acid synthesis [13]. 
Although insulin is a central regulator of the lipogenic pathway, it is now accepted that 
glucose also generates an independent signal [14, 15]. Glucose should not be uniquely 
considered as an energy fuel but also as a signaling molecule necessary for de novo 
lipogenesis, acting in synergy with insulin. L-PK gene expression is stimulated by glucose 
independently of insulin, in primary cultures of hepatocytes expressing GK [16]. Therefore, 
metabolism through GK is required to initiate glucose signaling [17]. Glucose-regulated genes 
share a conserved consensus sequence, named carbohydrate response element (ChoRE), 
which is required for their glucose-responsiveness [18, 19]. The identification of ChREBP 
[20], which belongs to the Mondo family of bHLHZiP transcription factors, has shed light on 
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the mechanism whereby glucose affects gene transcription [21, 22]. ChREBP silencing 
prevents the glucose-mediated induction of L-PK, ACC and FAS genes in hepatocytes [17]. 
In a physiopathological context, liver-specific inhibition of ChREBP improves hepatic 
steatosis and insulin resistance in ob/ob mice [23, 24]. Since ChREBP may represent a 
potential target for lipid-lowering therapies in obesity and diabetes, an accurate knowledge of 
the mechanism regulating its expression and activity is needed. ChREBP expression can be 
regulated by key nuclear receptors of energy homeostasis, namely LXR [25, 26] and the 
thyroid hormone receptor (TR) [27, 28]. Furthermore, ChREBP interacts with the nuclear 
receptors HNF4α [29] and COUP-TF II [30] to modulate the transcription of its target genes 
such as the L-PK. The aim of this review is to report novel findings on the function and the 
regulation of ChREBP. In particular, we will describe how, depending on the hormonal and/or 
nutritional status, specific nuclear receptors establish cross-talks with ChREBP to regulate the 
signaling pathways that control glucose and lipid homeostasis.  
 
Identification of ChREBP and of its partner lx 
ChREBP was discovered in 2001 by the group of K. Uyeda [20] on the basis of 
complementary studies revealing a glucose response element in the promoter of several 
lipogenic genes (called ChoRE), and composed of two E box (CACGTG) or “E box like” 
sequences separated by 5 base pairs [19, 31, 32, 33]. Using the ChoRE of the glycolytic 
enzyme L-PK, Yamashita et al. [20] identified ChREBP as a protein enriched in liver nuclear 
extracts from high carbohydrate diet fed rats. Binding of ChREBP was affected by change of 
spacing between the two E-box or mutation of the ChoRE. Following these experiments, 
ChREBP was purified and recognized as the homolog of the human protein named 
WBSCR14 or MondoB, and known to be deleted in the Williams-Beuren syndrome (WBS) 
[34]. Seventy-five % of WBS patients exhibit impaired glucose tolerance or silent diabetes 
that may be due to a loss of ChREBP [35]. Several features of ChREBP are consistent with a 
role as a glucose–regulated transcription factor. Its expression is most abundant in liver, small 
intestine, kidney, white and brown adipose tissue [36], which are the most active sites of de 
novo lipogenesis in the body. ChREBP mRNA has also been detected in distinct brain regions 
[37] and in rat pancreatic islets [38]. In addition, ChREBP expression is induced in liver in 
response to high carbohydrate diet, but not in response to polyunsaturated fatty acids diet fed 
or fasting [39]. Similarly to SREBP-1c, ChREBP is a member of the bHLHZiP (Basic-helix-
loop-helix leucine zipper) family of transcription factors, highly conserved among species. 
ChREBP was first shown to induce the transcriptional activity of the L-PK promoter in 
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hepatocytes cultured under high glucose concentrations [20]. To address the direct role of 
ChREBP, we used a siRNA approach to down regulate ChREBP expression in mouse 
hepatocytes. Our studies revealed, for the first time in a physiological context, that ChREBP 
mediates the glucose effect on L-PK but also on lipogenic genes (ACC, FAS) and that this 
transcription factor is a key determinant of lipid synthesis in liver [17]. ChREBP was later 
shown to directly bind the promoter sequences of L-PK and of lipogenic genes using 
chromatin immunoprecipitation (CHiP) analysis [22]. These results were confirmed by the 
characterization of mice lacking the ChREBP gene (ChREBPKO mice) [36]. When maintained 
on a standard diet, ChREBPKO mice display larger, glycogen-laden livers, smaller adipose 
depots, and decreased plasma free fatty acid levels. Importantly, ChREBPKO mice show 
impaired glycolytic and lipogenic pathways in liver and exhibit glucose and insulin 
intolerance.  
Soon after ChREBP discovery, using yeast two-hybrid system, Towle and co-workers 
identified a bHLHZiP protein, Mlx (Max-like protein X) that interacts with the bHLHZiP 
domain of ChREBP [21] (Figure 1). Mlx is a member of the Myc/Max/Mad family of 
transcription factors that can serve as a common interaction partner of a transcription factor 
network [40]. The evidence that Mlx is the functional partner of ChREBP was demonstrated 
through the use of an adenovirus expressing a dominant negative form of Mlx (dn-Mlx) [41]. 
The inhibition of Mlx directly interferes with the endogenous ChREBP/Mlx complex and 
abrogates the glucose-response of the ACC reporter gene in primary cultures of hepatocytes 
[41]. The response to glucose can be however partially restored when ChREBP is 
overexpressed. The regulatory domains of the ChREBP and Mlx proteins have been studied in 
great details over the last years [21, 41, 42]. According to the model proposed by Ma et al. 
[42], two ChREBP-Mlx heterodimers bind the two E boxes of the ChoRE to provide a 
transcriptional complex necessary for glucose regulation. Using a structural ChREBP/Mlx 
structural model followed by specific mutation experiments, three critical residues (F164, 
I166 and K170) within the Mlx loop that play a crucial role in the binding of the 
ChREBP/Mlx complex to the ChoRE have been identified [42]. Therefore, it appears that the 
Mlx loop region, but not the one of ChREBP, is determinant for mediating the response of 
glucose. Mlx has a significantly longer loop domain than most other bHLHZiP proteins, 
allowing it to potentially interact across the interface between heterodimer pairs. It is 
therefore possible that other proteins, via interactions involving the Mlx loop, could assist the 
binding of the ChREBP/Mlx complex to the ChoRE. It was recently reported that adenoviral 
overexpression of dn-Mlx in 25-week-old male C57BL/6J mice reduces hepatic TG content 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 8
and improves glucose intolerance by inhibiting expression of glucose-6-phosphatase (G6Pase) 
in addition to lipogenic enzymes. A distal promoter region of the G6Pase promoter was 
previously reported to be glucose responsive in 832/13 cells. The fact that ChREBP binds this 
region in a glucose-dependent manner [43], supports the fact that G6Pase is most likely a 
direct target of the ChREBP/Mlx complex.  
 
Regulation of ChREBP activity by glucose 
The regulation of ChREBP activity in response to glucose is complex. To date, two 
mechanisms reporting the glucose-mediated activation of ChREBP have been proposed: one 
involving on a two-step activation by dephosphorylation on specific residues [44] and one 
independent involving a dynamic intra-molecular inhibition between two regulatory domains 
within the ChREBP protein [45] (Figures 1 and 2). ChREBP is a large protein (864 amino 
acids and Mr=94,600) that contains several important domains including a nuclear 
localization signal (NLS) near the N-terminus, polyproline domains, a basic loop-helix-
leucine-zipper (bHLHZip), and a leucine-zipper-like (Zip-like) domain (Figure 1). Deletion of 
the NLS impairs ChREBP localization in the nucleus and prevents the glucose-induced 
transcriptional activation of a L-PK luciferase reporter construct in hepatocytes [46]. By 
studying the importance of ChREBP regulation by phosphorylation, Yamashita et al. reported 
that incubation of the protein ChREBP with the catabolic subunit of protein kinase (PKA) and 
ATP leads to an increase of its phosphorylation rate and a decrease of both nuclear content 
and DNA binding activity [20]. This effect could be reversed when a PKA inhibitor and/or the 
phosphatase 2A (PP2A) was added [20]. From these studies emerged a PP2A-dependent 
model of ChREBP activation and two important residues (Ser-196 and Thr-666) were 
identified as potential PKA target sites (Figure 1). Using a phospho-serine antibody, we 
showed that the glucagon-mediated phosphorylation of Ser-196 was correlated with ChREBP 
cytosolic localization [47]. Upon glucose stimulation, xylulose 5-phosphate (X5P), a 
metabolite of the pentose-phosphate pathway, was shown to promote ChREBP nuclear entry 
based on the specific activation of PP2A which dephosphorylates ChREBP on residue Ser-
196, located near the NLS (Figures 1 and 2). Within the nucleus, ChREBP DNA binding and 
transcriptional activation, would be triggered by a second dephosphorylation on Thr-666, also 
through a X5P- and PP2A-dependent mechanism [44, 46] (Figure 2). Consistent with this 
model, Wu et al [48] reported that ChREBP global phosphorylation status was decreased 
when glucose flux through GK, the rate-limiting enzyme of glycolysis was increased.  
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However, the regulation model of ChREBP by phosphorylation/dephosphorylation 
raised some controversy, due to questions concerning the involvement of X5P and/or PP2A 
[45, 49]. Some arguments suggested that glucose 6-phosphate (G6P) produced by GK could 
be, rather than X5P, the signal metabolite. First, the pentose phosphate pathway is not very 
active in pancreatic β-cells [50] while ChREBP is expressed and active in these cells [38, 51]. 
In fact, Li et al. [52] recently showed that G6P is sufficient and necessary to activate ChREBP 
transcriptional activity in INS1 832/13 β cells. Notably, the authors demonstrated that 
inhibition of the hexokinase by mannoheptulose or overexpression of G6Pase, which reverses 
hexokinase reaction by dephosphorylating G6P, abolishes glucose responsiveness of a gal4-
ChREBP reporter construct. Overexpression of glucose 6-phosphate dehydrogenase 
(G6PDH), the limiting enzyme of the pentose pathway which converts G6P to 6-
phosphogluconolactone, is accompanied by a dramatic decrease in G6P concentrations and 
leads to an inhibition of ChREBP glucose response in 832/13 INS-1 cells [52]. In contrast, 
silencing of the enzyme leads to the reverse phenotype, with enhanced G6P concentrations 
associated with increased ChREBP transcriptional activity [52]. Based on these recent 
findings in 832/13 INS-1 cells, it would be also important to determine the exact nature of the 
metabolite signal (G6P vs. X5P) that mediates the effect of glucose in liver cells.  
Another important point against the potential X5P-mediated activation of ChREBP is 
that 2-deoxyglucose (2-DG), a glucose analog which is phosphorylated by hexokinase but can 
not be metabolized downstream of the glycolytic metabolic pathway, is able to activate the 
transcriptional activity of ChREBP in 832/13 INS-1cells [52]. In addition, the fact that 
inactivating mutations of ChREBP on PKA phosphorylation sites including Ser-196 and Thr-
666 are still responsive to high glucose concentrations, is not in favor of the model proposed 
reporting that mutated ChREBP (i.e. on both Ser-196 and Thr-666) acts as a constitutive 
active ChREBP isoform, under low and high glucose concentrations [49]. Since inhibition of 
PP2A by cantharic acid did not alter the glucose responsiveness of a ChREBP construct fused 
with a gal4-DNA binding domain, Li and coworkers proposed an alternate model of post-
translational regulation for ChREBP in 832/13 INS-1cells [45] (Figures 1 and 2). By structure 
function analysis, a glucose-sensing module (GSM) evolutionally conserved in mondo 
proteins, which contains a low glucose inhibitory domain (LID) and a glucose response 
conserved element (GRACE) was identified within the ChREBP protein [45] (Figure 1). LID 
is able to inhibit the ChREBP transactivative activity conferred by GRACE, and this 
inhibition is lifted under high glucose conditions. A deleted form of the 196 first amino acids 
of ChREBP lacking LID in Nter is active even in low glucose concentration, despite the 
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integrity of Thr665 (equivalent to Thr666 in mice) and more importantly despite the loss of 
the NLS. So far, phosphorylation has been the only post-translational modification described 
to modulate ChREBP activity, but recent work from our laboratory revealed that ChREBP is 
also regulated by acetylation on specific lysines in response to glucose [53]. 
Lastly, ChREBP is exported from the nucleus by a mechanism requiring CRM1 
(Chromosome maintenance region 1), a protein that shares sequence similarities with the 
karyopherin β family of proteins involved in nuclear import pathway, was shown to form a 
complex with the leucine-rich nuclear export signal (NES) and the ability to bind the 14-3-3 
protein [54]. When the NES (NES1, located at residues 5-15 in the rat isoform) (Figure 1) is 
mutated [55], the binding of ChREBP to 14-3-3 and CRM1 is dramatically decreased [55]. 
Deletions or mutations of the key ChREBP domains, MCRII (MCR: Mondo Conserved 
Region) (containing the NES1) [55] [56] or MCRIII (containing the 14-3-3 binding site) [56, 
57] (Figure 1) lead to an increase in ChREBP nuclear localization and both mutants keep 
DNA binding activity [55]. Oddly, these ChREBP mutants display a significant loss in 
transactivative activity under both low and high glucose conditions, suggesting that ChREBP 
nuclear localization is not sufficient to mediate its transcriptional effects. In fact, another 
study casts doubt on the importance of ChREBP nuclear translocation. Davies et al. [57] 
reported that the majority of ChREBP protein is localized in the cytosol under both low and 
high glucose conditions in 832/13 INS-1 cells. Inhibition of the CRM1-induced nuclear 
export using leptomycin B treatment trapped ChREBP protein in both glucose conditions, 
suggesting a continuous shuttle of the protein between cytosol and nucleus [57] rather than an 
active translocation. Nevertheless, in this study the rate of nuclear entry of ChREBP was 
greater under high glucose concentrations.  
 
Transcriptional regulation of ChREBP: novel implication of nuclear receptors Liver X 
receptor (LXR) and thyroid hormone nuclear receptor (TR) 
Much research has been directed towards determining the post-translational control of 
ChREBP of glucose/glucagon (Figures 1 and 2) while only fewer studies have started to 
document its transcriptional regulation (Figure 3). ChREBP is induced at the mRNA level in 
liver in response to high carbohydrate diet, but not in response to high fat diet fed or fasting 
[39]. ChREBP expression clearly depends on the metabolization of glucose via GK. We have 
shown that the induction of ChREBP is markedly reduced in the liver of high carbohydrate 
diet fed GK deficient mice [17]. Overexpression of GK rescues the expression of glucose-
dependent genes in liver of streptozotocin (STZ) treated mice and this independently of 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 11
insulin/SREBP-1c, underlining the importance of glucose metabolism in ChREBP activity 
[58]. However, the molecular mechanism triggering the glucose-mediated regulation of 
ChREBP expression has not yet been elucidated. Despite the lack of identification of a well-
conserved ChoRE on the mouse ChREBP promoter (Figure 3), it has been suggested that 
ChREBP could regulate its own expression [42]. Indeed, overexpression of dn-Mlx decreases 
glucose-induced ChREBP expression. The hypothesis of ChREBP/Mlx self-regulation is 
interesting although it cannot be excluded that other transcription factors/co-receptors be 
recruited for the transcriptional control of ChREBP in response to glucose. A direct control of 
ChREBP expression by insulin was even reported. First, Satoh et al. showed that SREBP-1c 
binds a SRE (-101 to -110 bp) motif (Figure 3) within the ChREBP promoter in response to 
refeeding [60]. However, the fact that SREBP-1c overexpression failed to induce ChREBP in 
liver of fasted mice does not support the hypothesis of a direct control of ChREBP by 
SREBP-1c [17]. In addition, ChREBP is adequately induced upon refeeding in liver of LXR 
deficient (LXRKO) mice, and this in the absence of mature form (i.e. transcriptionally active) 
of SREBP-1c [47]. Interestingly, Sirek et al. [61] recently reported that the stimulatory effect 
of insulin on ChREBP could be independent of SREBP-1c but would rather involve Oct1, 
another transcription factor. Oct1 would act as a repressor of ChREBP activity: insulin would 
stimulate ChREBP transcriptional activity by inhibiting the binding of Oct1 on a POU 
domain. However, it should be noted that the reported effect of Oct1 on ChREBP 
transcriptional activity was very modest [61].  
Recently, two nuclear receptors playing important roles in energy homeostasis, namely 
LXR and TR, were shown to regulate ChREBP at the transcriptional level in liver [25, 27, 28] 
(Figure 3). LXRs (LXRα and LXRβ) act as sterol sensors activated by oxidized cholesterol 
derivatives called oxysterols [62, 63]. In contrast to LXRβ whose expression is ubiquitous 
[64, 65, 66, 67], LXRα expression is particularly high is liver, adipose tissue, intestine, but it 
is also present in spleen kidney and lung. LXR forms an heterodimer with RXR (retinoid X 
receptor) and binds LXRE sequence(s) within target gene promoter region [64]. LXRs are 
particularly important for cholesterol metabolism, in which they contribute to excess 
cholesterol elimination. LXRα controls bile acids synthesis via the induction of Cyp7A1 gene 
in rodents [62, 68], cholesterol excretion in bile acids in liver [69-71] and cholesterol efflux 
from several cell types via the regulation of ABCA1 and ABCG1 transporters [9, 72-74]. The 
transcriptional activity of the thyroid hormone L-triiodothyronine (T3) has been known since 
1960 [75], but the cloning of its responsive receptor, the thyroid hormone nuclear receptor 
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(TR), occurred only in 1986 [76, 77]. In mammals, two different genes TRα and TRβ code 
for the thyroid receptors TRα1, TRβ1, TRβ2, and TRβ3 [78]. The expression of TRβ1 is high 
in liver, in which TRα1 is less abundant [78]. Interestingly, several studies reported that LXR 
and TR are closely related. First, LXRs and TR recognize the same consensus sequence: 
AGGTCA repeated with a 4 base pair gap (DR4) [79-81]. In some cases, both nuclear 
receptors can bind the same responsive element on a promoter. For example, TR competes 
with LXR for the binding of the LXRE on the ABC1 promoter and can inhibit the LXR-
induced ABC1 expression [82]. Moreover, un-liganded TRβ1, which is known to act as a 
transcriptional repressor [83], interacts with co-repressors to repress the transactivative 
activity of LXRα by competing on the LXRE of SREBP-1c promoter in vitro [84]. 
Furthermore, LXRα has been described as a direct TRβ1/T3 target gene in mouse liver, 
through the recruitment of TRβ1/RXRα (site A : -1300 to -1240 bp) [85]. However, this 
induction of LXRα and of its target gene ABC 1 by T3 was not confirmed in a follow-up 
study [28]. 
The implication of LXR in the control of the lipogenic pathway was evidenced in 
LXRαKO mice, as they present a decrease in SREBP-1c and in several of its target genes in 
liver [8, 86, 87-89, 90, 91]. Two functional LXREs have been identified in the SREBP-1c 
promoter [9, 92]. LXR stimulation with its most efficient synthetic agonist, T0901317, allows 
the increase of SREBP-1c, ACC, FAS and SCD1 expression in liver and increases hepatic and 
plasma TG in wild type but not in LXRα/βKO, LXRαKO mice or SREBP-1cKO mice [11, 13, 
93, 94]. The physiological stimulation of SREBP-1c expression occurs in the presence of 
insulin, but the link between LXR and insulin remains unclear. Tobin et al. suggested that 
insulin stimulates LXRα expression in rat hepatocytes [95]. However, the physiological 
relevance of this regulation is disputed since supra-physiological concentrations of insulin (up 
to 500 nM) were used in this study [95]. Nevertheless, SREBP-1c is not induced by insulin in 
LXRα/βKO mice and the functional LXREs within the SREBP-1c promoter are necessary for 
its induction by insulin [10]. The most logical link between insulin and LXR would be that 
the hormone somehow stimulates the synthesis of a LXR ligand necessary for the action of 
the nuclear receptor.  
Treatment of wild type mice with thyroid hormone (TH) induces lipogenic gene 
expression (including ACC and FAS) and TRβ1KO mice display decreased expression of these 
genes [96]. The identification of ChREBP as a novel LXR and TR target gene [25, 27, 28] 
(Figure 3) is interesting and underlines the role of these two nuclear receptors in the control of 
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the lipogenic pathway. First, Cha and Repa reported that ChREBP mRNA levels were 
increased by about 3 fold in livers of fed mice treated with either dietary RXR or LXR 
agonists, (and by 6 fold when a combination of both agonists was used) [25]. These effects 
are specific since ChREBP expression was not induced in liver of LXRKO mice treated with 
the LXR agonist (T0901317) for short (12h) or longer periods of treatment (10 days). This 
treatment was associated with a loss of induction of ChREBP-target gene, L-PK. In addition, 
the effect of T0901317 on lipogenic genes (ACC, FAS and SCD1) was attenuated in 
ChREBPKO mice [25]. The mouse ChREBP promoter contains two functional LXRE able to 
bind the LXR/RXR complex thereby conferring its receptor/ligand transactivation (Figure 3). 
It should be noted that LXRE1 showed a greater activity than LXRE2 for LXR binding.  
Two recent studies supported the control of ChREBP by thyroid hormones (TH) [27, 
28]. In mice turned into a hypothyroid state by a MMI/PTU diet (containing methimazole and 
propylthiouracil, two inhibitors of TH synthesis), hepatic ChREBP expression (mRNA and 
protein content) was decreased by about 40% compared to controls. In parallel, hypothyroid 
mice injected with TH (T3), thus becoming thyrotoxic, present a 3- to 4-fold increase in 
ChREBP expression [27]. Importantly, in two models of hypothyroid states, pax8KO mice 
(deprived of thyroid gland) and wild type mice submitted to PTU (PTU: Propylthiouracil used 
to decrease the synthesis of endogenous TH) treatment, ChREBP expression can be rescued to 
control levels after TH injection, and this to a greater extent in white adipose than in liver 
[28]. Modulation of hepatic ChREBP expression in relation to the thyroid state in PTU/MUI 
mice [27] or in pax8KO mice injected with TH [28] were paralleled with changes in its target 
genes [28]. In both liver and adipose tissue, the effect of TH on lipogenic gene expression in 
PTU-treated mice was lost in TRβKO but not in TRαKO mice, reinforcing the previously 
described role of TRβ in lipogenesis [96] and revealing its control on ChREBP expression. 
Interestingly, ChREBP expression was repressed when wild type mice, but not TRβKO mice, 
were submitted to a PTU diet, suggesting that un-liganded TRβ represses ChREBP expression 
[28].  
Both TRβ and TRα were able to activate the mouse ChREBP promoter in vitro [28]. 
Luciferase assays confirmed that T3 increases the activity of the mouse and the human wild 
type ChREBP promoter but not when the LXRE1 and LXRE2 were deleted [27]. 
Interestingly, mutation of each or both LXREs on the ChREBP promoter did not lead to a 
complete loss of LXR or TR response, raising the possibility that other regions mediating the 
LXR and/or TR response may exist on the ChREBP promoter [28]. The heterodimer TR-
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β1/RXRα was able to bind the LXRE2 of the mouse ChREBP promoter, but not the LXRE1, 
which was shown to be the preferential site for LXRα/RXRα [25] (Figure 3).  
This interesting crosstalk between LXR and TR was further explored in LXRKO mice 
[28]. In PTU-treated LXRKO mice, hepatic ChREBP expression was induced in response to 
TH, demonstrating that the TH-mediated induction of ChREBP was independent of LXR. 
Surprisingly, ChREBP expression in response to TH was higher in liver of LXRKO than in 
wild type mice, suggesting that LXR, when bound to the LXRE1, might limit the access of 
TRs on the LXRE2. Co-transfection assays of LXR and TRβ with one of the two specific 
ligands (T0901317 or TH) confirmed this hypothesis. Transfected alone TRβ or LXR induced 
the ChREBP promoter activity in the presence of their cognate ligands (TH and T0901317) 
while co-transfection of both (TRβ and LXR) decreased the response of the ChREBP 
promoter to each ligand (TH and T0901317). Altogether, these data reveal that TH induces 
ChREBP transcription and protein content in liver in vivo and in cells, and that the LXRE2 is 
central in this regulation (Figure 3). Paradoxically, Hashimoto et al. previously reported that 
SREBP-1c was repressed by T3 in mouse liver [97] and similar results were reported in 
human adipocytes [98]. These results are controversial since studies in the chick embryo 
hepatocytes (CEH) [99] and in HepG2 cells [84] led to opposite results. The understanding of 
the physiological relevance of such an antagonism between ChREBP and SREBP-1c requires 
further investigation. 
 
 
Physiological relevance of the regulation of ChREBP by LXR and/or TR in liver: a role in 
glucose-sensing ? 
 An important point that remains to be determined is the physiological relevance of the 
regulation of ChREBP by LXR and/or TR. Since ChREBP is mostly regulated by 
glucose/glucose metabolism, studies were first performed to determine the potential 
implication of LXR and/or TR in the nutritional regulation of ChREBP. Fasting/refeeding 
experiments in wild type or TRβKO mice revealed that ChREBP expression is increased to 
comparable levels in livers of refed mice from both genotypes, suggesting that TR is not 
involved in the nutritional regulation of ChREBP [28]. In fact, addition of TH led to an 
increase in ChREBP and lipogenic genes (FAS for example) in the fasted state but did not 
allow further induction in the fed state [28].  
The implication of LXR remains, to date, somehow controversial since some set of 
studies reported that LXR might be implicated in the glucose signaling pathway [26, 100], 
while some were against this hypothesis [47, 101]. A lot of emphasis came from the study of 
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Mitro et al. [26], which placed LXR at the center of the glucose-mediated regulation of 
hepatic lipogenesis.  It was reported that a gal4 reporter construct of the ligand binding 
domain (LBD) of LXR fused to a DNA binding domain (DBD) of yeast gal4 was highly 
responsive to D-glucose in HepG2 cells. In addition, the activity of a LXRE-luciferase 
reporter construct was found to be activated in the presence of D-glucose and/or G6P in 
HepG2 cells co-transfected with a LXR expression plasmid. Interestingly, this stimulatory 
effect of D-glucose/D-G6P on LXR reporter activity was comparable to the one of T0901317. 
FRET assay revealed that D-glucose and D-G6P induced the recruitment of LXRs co-
activators and this to similar levels than T0901317. Surprisingly, L-glucose was also 
presented as a direct agonist in FRET assay. Moreover, Mitro et al. reported that addition of 
glucose to a maximal dose of synthetic ligand further increased the recruitment of LXR co-
activators [26]. Since labeled D-glucose and D-G6P were able to compete with synthetic LXR 
ligands, the authors suggested that glucose was able to bind on specific LXR sites. Altogether, 
this study suggested that LXRα could serve as a glucose-sensor detecting glucose excess and 
converting it into TG by inducing lipogenic genes directly or indirectly via ChREBP and 
SREBP-1c [26]. Several objections were raised against this model. First, we [47] and 
Oosterveer et al. [102] reported that ChREBP expression, its nuclear translocation and the 
induction of its target gene, L-PK, were not altered in response to high carbohydrate diet in 
liver of LXRα/βKO mice, suggesting that effect of glucose on ChREBP is independent of LXR 
[47]. Secondly, the expression of LXR target genes ABCG1, ABCA1, ABCG5 and ABCG8 
was not affected by high carbohydrate diet feeding in liver of wild type or LXRα/βKO mice, 
suggesting that direct LXR targets are not nutritionally regulated [47, 102]. The relevance of a 
direct binding of glucose/G6P on LXR was also challenged because of the hydrophilic nature 
of glucose, its weak affinity (in mM) compared to other nuclear receptor ligands and more 
importantly due to the inability of G6P to properly enter the cells. Finally, L-glucose was 
presented as very rarely active in biological process [101]. Along these lines, we were not 
able to reproduce in a cell-free assay the ability of either D-glucose or G6P to influence the 
interaction between LXRα or LXRβ, and their known co-activator peptides [47]. 
Interestingly, the respective roles of ChREBP and LXR in controlling lipogenic genes were 
further addressed in a mouse model of glycogen storage disease type 1 (GSD-1) [103]. 
Treatment of mice with S4048, a pharmalogical inhibitor of the glucose 6-phosphatase 
transporter, which is part of G6Pase, recapitulated the metabolic defects associated with GSD-
1: reduction in blood glucose levels, increased G6P, glycogen and TG concentrations. S4048-
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treatment was also associated with a marked increased in lipogenic gene expression, through a 
ChREBP-dependent mechanism. More importantly, this study reveals that G6P is not able to 
activate LXRα in vivo and therefore does not support the hypothesis that G6P could be a 
direct ligand for LXR as previously reported [26].  
Taken together, a direct link between glucose/G6P and LXR seems uncertain. 
However could another kind of regulation by glucose exist for LXR? A study reported that 
LXRs could be modified by O-linked ß-N-acetylglucosamine (O-GlcNAcylation or O-
GlcNAc) in Huh7 cells [100]. O-GlcNAcylation plays an important role in the modulation of 
protein stability, cellular localization, activity and partner interactions [106] and key 
transcription factors were recently shown to be modified by O-GlcNAcylation in liver [100, 
104, 105]. O-GlcNAcylation is the end product of the hexosamine biosynthetic pathway 
(HBP), a metabolic pathway which has recently emerged as a major determinant of metabolic 
disorders associated with insulin resistance and/or type 2-diabetes. Anthonisen et al. [100] 
demonstrated that O-GlcNAcylation of LXR is elevated in liver of fed mice and in Huh7 cells 
incubated in high glucose concentrations. In liver of mice rendered diabetic with a STZ 
treatment, (i.e. characterized by hyperglycemia in nearly absence of insulin), LXR O- O-
GlcNAcylation was higher than in non-diabetic controls and was correlated with a greater 
induction of LXR-target gene, SREBP-1c [100]. In this study, it would have been interesting 
to study the effects of LXR O-GlcNAcylation on ChREBP activity in order to establish a 
potential link between glucose, LXR and ChREBP. Nevertheless, it would be interesting to 
determine whether enhanced LXR O-GlcNAcylation levels in liver of diabetic mice can 
explain the induction of ChREBP under hyperglycemic states.  
One interesting physiological situation in which a cross-regulation between LXR and 
TR could occur is the suckling-weaning transition. Bobard et al. [107] reported that LXR 
expression and binding activity is high during the suckling period (a period during which 
mice consume milk rich in cholesterol and lipids but poor in carbohydrates), leading in turn to 
an increase in SREBP-1c precursor protein levels. The SREBP-1c protein is not cleaved 
during this period because insulin concentrations are low, and as a consequence the 
expression of its target genes (GK and FAS) remains low. This suggests that the increase in 
SREBP-1c precursor forms during the suckling period, in response to activated LXRα, could 
prepare the liver to rapidly convert in fat the increase of carbohydrates that occurs at weaning 
due to the switch of diet. Following the same model, and given that rodents display an 
increase of T3 concentrations during the last days of the suckling period [108], it could be 
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envisioned that LXRα and/or TRβ increase ChREBP expression in a carbohydrate-
independent manner during this period of development. 
Lastly, a potential link between polyunsaturated fatty acids (PUFAs), LXR and/or TR 
and ChREBP could be envisioned. Through mechanisms only partially understood, long-
chain n−3 PUFAs have the ability to control the transcriptional activity of nuclear receptors 
and, thereby, the transcription rate of specific genes related to lipid and carbohydrate 
metabolism [109]. n−3 long-chain PUFAs bind to peroxisome proliferator-activated receptors 
(PPARs) α, β, γ1 and γ2 [110] and the actions of PUFAs are, in great part, mediated by 
PPARs. However, PUFAs also bind to other nuclear receptors such as LXRα [111], 
hepatocyte nuclear factor-4 (HNF4α and γ) [112, 113] and RXR [114]. Another mechanism 
involved in the actions of PUFAs is the decrease in the nuclear abundance of SREBP-1c, 
ChREBP [39] and Mlx [115]. Considering the transcriptional control exerted by LXR on 
ChREBP [25], it would be interesting to determine whether some of beneficial effects of 
PUFA on hepatic lipogenesis and TG synthesis, are triggered, at least in part by ChREBP 
through a LXR dependent pathway. A similar molecular mechanism for TR does not seem 
conceivable since it was reported that long-term consumption of n−3 PUFAs enhances 
thyroid hormone action in mouse liver [116]. Further studies will be required to better 
understand a potential contribution of TR to the TG-lowering effect of PUFA.  
 
The glucose-regulated L-PK gene model: an interplay between ChREBP and key nuclear 
receptors 
With the discovery of ChREBP, our understanding of the transcriptional effect of 
glucose in liver has made considerable progress. The glycolytic enzyme L-PK, whose 
expression is strictly dependent on glucose/glucose metabolism is now widely considered as a 
ChREBP-dependent gene. Its expression has been studied for many years as it represents a 
model gene for other glucose-regulated genes. A 200 bp of the 5’ region of the L-PK 
promoter was shown to be glucose-responsive in rat hepatocytes [18]. Within this region four 
response elements, including L3 and L4 were identified [117], The L3 and L4 are closely 
located from nucleotides -145 to -125 for the L3 and from -168 to -144 for the L4 (Figure 4). 
In 1992, Bergot et al. demonstrated that the maximal induction of the L-PK promoter by 
glucose requires a necessary interaction between the sequence responsive for HNF4α, the L3 
site and the L4 site, now known as containing the ChoRE [19] (Figure 4). HNF4α, also called 
NR2A1, is a nuclear receptor that has recently be reported to bind in a reversible way linoleic 
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acid in liver of fed mice [118]. HNF4α is expressed in adult liver but also in the 
gastrointestinal tract, kidney and pancreas [119]. This transcription factor, conserved in 
evolution, plays an important role in embryonic development in xenopus [120] and in 
mammals. Liver specific HNF4α knockout mice die at about the eighth week of life with 
alterations of gene expression involved in lipid and bile acid metabolism [121]. HNF4α 
mutations are also implicated in rare case of Maturations Onset Diabetes of the Young 
(MODY) [122, 123]. Diaz-Guerra et al. demonstrated that the principal factor binding to the 
L3 sequence of the L-PK promoter in rat liver nuclear extracts was HNF4α, despite the 
presence of other several transcription factors including nuclear receptor COUP-TFII as we 
will discussed below [124]. Overexpression of HNF4α alone is able to induce the activity of 
the L-PK promoter in fibroblastic NIH 3T6 cell lines devoid of endogenous HNF4. 
Interestingly, transfection of the HNF4α isobinder COUP-TFII in primary hepatocytes 
inhibits in a L3-dependent manner the activity of a L-PK promoter, probably due to a 
competition between these two nuclear receptors. While the implication of HNF4α on the 
transcriptional control of the L-PK gene is well admitted, its regulation in response to glucose 
is controversial and remains to be clearly determined. On one hand, Xu et al. reported that the 
nuclear abundance of HNF4α was not modified in liver of refed rats, nor its binding to the L-
PK promoter in primary rat hepatocytes in response to glucose [115]. Secondly, Eckert et al. 
showed that HNF4α was constitutively bound to the L-PK promoter under low glucose 
concentrations, and that this binding was increased by high glucose concentrations [125]. 
Recently, Burke and co-workers presented an elegant model in which a protein complex 
containing ChREBP, HNF4α and the co-activator CBP is necessary for the glucose-mediated 
induction of the L-PK gene (Figure 4) [29]. SeqChIP experiments in 832/13 INS-1 cells 
revealed the recruitment of ChREBP, HNF4α and CBP in response to high glucose 
concentrations on the L-PK promoter, a recruitment that is decreased by forskolin, 
demonstrating that the cAMP pathway alters their occupancy on the L-PK promoter despite 
the presence of glucose. Previous studies evidenced an association between HNF4α and the 
transcription co-activator CBP [126, 127] (Figure 4). Decreased CBP expression by siRNA 
led to the loss of glucose-induced L-PK expression [29] and in contrast, CBP overexpression 
was sufficient to overcome the repression by forskolin of the wild type L-PK promoter 
activity but not of the L-PK promoter construct mutated on the ChoRE. Furthermore, when 
the responsive element of HNF4α, L3, was mutated, the glucose induction of L-PK promoter 
activity was blocked, in the presence or the absence of CBP overexpression. Interestingly, 
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overexpression of wild type ChREBP or a mutant of the three known PKA phosphorylation 
sites (mutants S196A, S626A, T666A), did not overcome the repression induced by forskolin 
on the L-PK promoter [29]. 
These results demonstrate that CBP is limiting for the formation or the disruption of 
the CHREBP/HNF4α/CBP complex in response to glucose or cAMP signal (Figure 4). 
Lastly, Perilhou et al. established a potential link between COUP-TFII and ChREBP. COUP-
TFII was first identified as a homodimer that binds the direct repeat site (DR-1) on the 
chicken ovalbumin promoter [128]. Later it was shown that this nuclear receptor acts mostly 
as a transcriptional repressor through its interaction with co-repressors [129] or through a 
titration of the nuclear receptor RXR, a transcriptional partner of several other nuclear 
receptors. COUP-TFII is expressed, among others, in metabolic tissues such as liver, adipose 
tissue, skeletal muscle and endocrine pancreas [130]. COUP-TFII represses insulin genes and 
insulin secretion in 832/13 INS-1 cells [30]. Specific deletion of COUP/TFII in β-cells leads 
to an impairment of glucose tolerance and of the glucose-induced insulin secretion in mice 
[131].  
COUPTF-II was first cloned in rat liver nuclear extracts using one-hybrid selection 
approach in yeast. While COUP-TF II was previously shown to bind the L3 sequence and 
compete with HNF4α as we discussed above, it was reported that COUPTF-II was also able 
to bind on two direct repeat sequences (DR-1 and DR-7 sites) within the L4 region of L-PK 
promoter [132]. These DRs sites overlap with the first E-box of the ChoRE. Interestingly, 
COUP-TFII was shown to induce and to be induced by HNF4α, and COUP-TFII can repress 
its own expression by competition with HNF4 α for binding on its own promoter [30]. 
COUP-TFII expression is repressed by glucose and insulin signals in liver in vivo and in 
primary cultures of hepatocytes suggesting that glucose metabolism is essential for COUP-
TFII inhibition [30]. In agreement with this hypothesis, the glucose-mediated repression of 
COUP-TFII is lost in liver of GKKO mice. In addition, in liver of obese and diabetic ob/ob 
mice in which ChREBP expression is elevated [23], a parallel decrease in COUP-TFII 
expression was observed. This decrease can be rescued when ChREBP is down-regulated 
using a shARN strategy [30]. Altogether, these results support the idea that ChREBP may 
indirectly or directly represses COUP-TFII expression and suggests that an active ChREBP 
may prevent the mediated repression of COUP-TFII on the L-PK promoter in hepatocytes 
within the L4 site under fed or high glucose conditions (Figure 4).  
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FXR, another important nuclear receptor was suggested to prevent the 
glucose/ChREBP-mediated induction of the L-PK gene [133]. FXR is a nuclear receptor 
controlling bile acid levels, notably by decreasing Cyp7A1 expression [134]. Interestingly, 
FXRKO mice display increased hepatic TG levels in the fed state along with an accelerated 
induction of glycolytic (LPK) and lipogenic (ACC) gene in response to high carbohydrate 
feeding [133]. Treatment of primary hepatocytes with GW4064, a FXR agonist decreases the 
glucose-induced expression of these genes. Therefore, FXR could be a direct mediator of the 
repression of glycolytic/lipogenic genes as it binds as a homodimer to the L3 region but not 
the L4 region on a L4-L3 luciferase L-PK promoter construct [133] (Figure 4). Although 
ChREBP expression was not reported to be modulated in liver of FXRKO mice, analysis of 
ChREBP nuclear localization and/or activity upon FXR activation would be useful in order to 
further understand the mechanism(s) by which FXR represses glucose-regulated gene 
expression.  
 
Concluding remarks 
The molecular control of hepatic glucose metabolism is complex as it requires an 
interplay of transcription factors and/or nuclear receptors in response to hormonal stimuli 
and/or nutrients [135]. Among them, we focused our attention on the action and regulation of 
ChREBP, which has emerged over the recent years, as a major determinant of glycolysis and 
lipogenesis control in response to glucose. Future studies will help identify other nuclear 
receptors that can either regulate and/or interact with ChREBP for the molecular regulation of 
the lipogenic pathway. For example, a recent study reported that agonists of PPARγ, VDR 
(vitamin D receptor), PXR (pregnane X receptor) or antagonists of FXR, CAR (constitutive 
androstane receptor), and ERα (estrogen receptor) are able to stimulate lipid accumulation in 
human hepatocytes and/or hepatoma cell lines [136]. For instance, the activation of PXR, a 
nuclear receptor mostly implicated in sensing and elimination of xenobiotic and drugs [137], 
leads to an increase in FAS and SCD1 expression, that is independent of a variation in 
SREBP-1c expression or nuclear abundance [138]. Although Moreau et al. [139] reported that 
the PXR-mediated activation of de novo lipogenesis in human hepatocytes was also 
independent of a variation in ChREBP expression, additional studies will be required to 
determine whether PXR agonists affect somehow ChREBP transcriptional activity and/or 
nuclear abundance. Interestingly, a study also recently reported that ChREBP acts as a critical 
and direct mediator of glucose repression of the PPARα gene in pancreatic β-cells suggesting 
that ChREBP may be important for glucose-suppression of β-oxidation in β-cells [140]. 
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Altogether, these potential novel molecular cross-talks may help identify new molecular 
targets for control of fatty acid synthesis and for the prevention of hepatic steatosis and 
related metabolic alterations.  
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Figure legends 
 
Figure 1. ChREBP protein structure. The ChREBP protein (864 amino acids; Mr= 94,600) 
contains several domains: a nuclear localization signal (NLS) (residues 158-173 in the rat 
isoform); two nuclear export signals (NES1 and NES2) located near the N-terminus (residues 
5-15 and 85-95 in the rat isoform) [55]; a polyproline domain and a leucine-zipper-like (Zip-
like) domain (residues 382-585 and 795-835, respectively in the human isoform,) [34]; and a 
basic loop-helix-leucine-zipper (bHLH/Zip) (residues 660-736 in the rat isoform) [45]. The 
MCRII (MCR: Mondo Conserved Region) (containing the NES1) [55] [56] and the MCRIII 
(containing the 14-3-3 binding site, localized between residues 125 and 135 in the rat 
isoform) [55, 56, 57] are also indicated. ChREBP contains at least three phosphorylation sites 
by protein kinase (PKA) (Ser196, Ser626 and Thr666 (mouse)/ Thr665 (rat)). Several other 
phosphorylation sites have been identified but are not indicated on this figure [141]. The 
functional partner of ChREBP, Mlx, interacts with ChREBP bHLHZiP domain as indicated. 
By structure function analysis, a glucose-sensing module (GSM) containing a low glucose 
inhibitory domain (LID, residues 37-192) and a glucose response conserved element 
(GRACE, residues 197-298) was identified in the rat ChREBP protein [45]. LID inhibits the 
ChREBP transactivative activity conferred by GRACE, and this inhibition is lifted under high 
glucose conditions. A deleted form of ChREBP 196 first amino acids lacking LID in the N-
terminus is active even under low glucose concentration, despite the integrity of Thr666 and 
more surprisingly despite the loss of the NLS. In addition, although not indicated on this 
figure, several acetylation sites on specific lysines have been identified on the mouse 
ChREBP protein [53].  
 
Figure 2. Transcriptional activation of lipogenic genes by ChREBP/Mlx, SREBP-1c and 
LXRα in liver. Insulin activates the transcription of the SREBP-1c gene leading to the 
synthesis of a precursor form of SREBP-1c (pSREBP-1c), which will be anchored in the 
membranes of the endoplasmic reticulum. Insulin activates the proteolytic cleavage of the 
precursor form and the processed mature SREBP-1c (mSREBP-1c) translocates to the nucleus 
where it activates lipogenic genes after binding to its regulatory binding elements (SRE) [7]. 
The phosphorylation of glucose in G6P, by hepatic GK, is an essential step for glucose 
metabolism as well as for the induction of lipogenic genes. To date, two mechanisms 
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reporting the glucose-mediated activation of ChREBP have been proposed: one involving on 
a two-step activation by dephosphorylation on specific residues (Ser-196 and Thr-666) two 
target sites of protein kinase A (PKA) [44] and one independent involving a dynamic intra-
molecular inhibition between two regulatory domains (LID and GRACE) within the ChREBP 
protein [45]. One and/or both of these mechanisms lead to ChREBP translocation into the 
nucleus under both high glucose and insulin concentrations. Within the nucleus, ChREBP 
binds the ChoRE and activates its target genes. ChREBP heterodimerizes with Mlx to mediate 
the glucose response: two ChREBP-Mlx heterodimers bind to the two E boxes of the ChoRE 
to provide a transcriptional complex necessary for glucose regulation. It remains to be 
determined where (cytosol vs. nucleus) the association between ChREBP and Mlx occurs and 
whether Mlx is regulated by glucose metabolism like ChREBP. LXRα directly binds to its 
regulatory binding site (LXRE) and contributes to the induction of lipogenic genes. However, 
the activation of LXRα in response to insulin and/or glucose remains unclear as discussed. 
Location of the ChoRE, LXRα and SRE motifs on the rat FAS promoter are indicated.  
 
Figure 3. Transcriptional regulation of ChREBP. The heterodimers LXRα/RXRα and 
TRβ1/RXRα transactivate the ChREBP promoter and induce its expression in the liver in 
response to their synthetic (LXRα) or natural (TRβ1) ligands. However, neither LXRα nor 
TRβ1 seem to be implicated in the regulation of ChREBP by glucose. Although it has been 
suggested that ChREBP could regulate its own expression [42], a functional ChoRE still 
awaits to be identified and characterized on the ChREBP promoter. However, a SRE motif 
was also identified suggesting a potential cross-regulation between SREBP-1c and ChREBP. 
 
Figure 4. Nutritional and/or hormonal regulation of the L-PK gene. In the fed state (in 
response to glucose metabolism), the ChREBP/Mlx heterotetramer, the nuclear receptor 
homodimer HNF4α and the co-activator CBP form a complex that binds to the glucose 
sensing domain L3/L4 on the L-PK promoter. As a result, L-PK expression is induced, 
allowing the last step of glycolysis to be activated. In response to glucose/glucose 
metabolism, ChREBP would repress COUP-TFII expression/activity by a mechanism not yet 
elucidated, thereby preventing COUP-TFII binding to the L3/L4 domain. Under fasting 
conditions (in response to the glucagon/camp signal), the ChREBP/Mlx/HNF4α/CBP 
complex is disrupted, does not bind to the ChoRE, thereby preventing the stimulation of the 
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L-PK gene. In addition, COUP-TFII and/or FXR, acting as transcriptional repressors on the 
L3/L4, would maintain L-PK gene silent.  
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